Publications by authors named "M T Drayson"
CD34 progenitor cells with angiogenic capabilities traffic into blood during exercise and extravasate afterwards but the magnitude of this response varies between people. We examined whether exercise-induced progenitor cell trafficking is influenced by cardiorespiratory fitness (maximum oxygen uptake; ). Ten males (age: 23 ± 3 years; : 61.
View Article and Find Full Text PDFNeutrophils, pivotal cells of innate and adaptive immune responses, employ reactive oxygen species (ROS) to combat pathogens and control gene expression. Paracetamol (acetaminophen) is widely used as an analgesic and antipyretic medication, yet its precise mechanisms of action are not yet fully understood. Here, we investigate the impact of both ingested and in-vitro paracetamol on neutrophil ROS activity, using flow cytometry and antioxidant assays.
View Article and Find Full Text PDFChimeric antigen receptor (CAR) T cells represent a novel targeted approach to overcome deficits in the ability of the host immune system to detect and eradicate tumours. 5T4 is a tumour-associated antigen expressed on the cell surface of most solid tumours. However, very little is known about its expression in haematological malignancies.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on short- and long-term antibody responses to pneumococcal vaccines in HIV-infected adults, comparing two types of vaccines: Pneumovax-23 (PPV) and Prevenar-13 (PCV).
- A subgroup of 152 participants from a larger study had their antibody levels measured before and after vaccination, with ongoing assessments for four years. Results indicated that those vaccinated with PCV had a higher likelihood of achieving the World Health Organization's antibody threshold than those who received PPV.
- Specifically, 54% of PCV recipients reached the target after one dose compared to 33% with PPV, and this advantage continued with booster doses, showing better cumulative rates
Article Synopsis
- The study evaluates the effectiveness of a treatment regimen (ixazomib, thalidomide, and dexamethasone) followed by maintenance with ixazomib after salvage autologous hematopoietic stem-cell transplantation (HSCT) for patients with relapsed multiple myeloma, compared to observation.
- Conducted as part of a larger trial (Myeloma XII) across 79 UK hospitals, it involved patients aged 18+ with measurable disease and certain health criteria, randomized into two treatment groups.
- The primary measurement for effectiveness was progression-free survival, with safety assessments also being conducted, and a total of 206 patients participated in this phase of the trial.